{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:37:17Z","timestamp":1790339837017,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.eururo.2014.11.031","type":"journal-article","created":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T21:39:33Z","timestamp":1417297173000},"page":"359-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Therapeutic Options in High-risk Non\u2013muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Gu\u00e9rin"],"prefix":"10.1016","volume":"67","author":[{"given":"A. Hugh","family":"Mostafid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Palou Redorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.11.031_bib0005","unstructured":"Mould at Toronto plant may affect supplies of cancer drug. Canadian Press Web site. http:\/\/www.cbc.ca\/news\/canada\/toronto\/mould-at-toronto-plant-may-affect-supplies-of-cancer-drug-1.1282152. Accessed November 4, 2014."},{"key":"10.1016\/j.eururo.2014.11.031_bib0010","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nrurol.2013.194","article-title":"BCG immunotherapy for bladder cancer--the effects of substrain differences","volume":"10","author":"Gan","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2014.11.031_bib0015","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.031_bib0020","unstructured":"Approach for consideration to address shortage of bacillus Calmette-Gu\u00e9rin (BCG). Bladder Cancer Canada Web site. https:\/\/bladdercancercanada.org\/images\/uploads\/pdf\/Approach_to_Address_BCG_Shortage__Sept_11,_2014_.pdf. Accessed November 4, 2014"},{"key":"10.1016\/j.eururo.2014.11.031_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.031_bib0030","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","article-title":"Bacillus Calmette-Gu\u00e9rin without maintenance therapy for high-risk non-muscle-invasive bladder cancer","volume":"60","author":"Herr","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.031_bib0035","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance BCG immunotherapy for recurrent TA,T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.11.031_bib0040","unstructured":"Martinez-Pineiro L, Hern\u00e1ndez R, Portillo JA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for TaG3 or T1G3 and\/or carcinoma in situ transitional cell carcinoma of the bladder: final results of the randomized CUETO group study 98013 [abstract 1007]. Presented at: European Association of Urology congress; April 11\u201315, 2014; Stockholm, Sweden."},{"key":"10.1016\/j.eururo.2014.11.031_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2011.04.023","article-title":"The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review","volume":"60","author":"Lammers","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.031_bib0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814012147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814012147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T12:23:41Z","timestamp":1583929421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814012147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0302283814012147"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.11.031","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Options in High-risk Non\u2013muscle-invasive Bladder Cancer During the Current Worldwide Shortage of Bacille Calmette-Gu\u00e9rin","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}